Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial

P. A. Testoni, E. Masci, F. Bagnolo, S. Passaretti, A. Pellegrini, G. Ronchi, G. Nappi, A. Tittobello

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirty-six subjects with endoscopic/histologic diagnosis of chronic reflux antral gastritis and with proven duodenogastric bile reflux were studied in a double-blind trial (cisapride, orally, 10 mg x 4/day vs placebo). The following determinants were considered in the study: endoscopy, histology, and dyspeptic symptoms. All except the endoscopic parameters were evaluated by means of a severity score (0 = absent to 3 = severe). Symptoms were assessed after four and eight weeks of treatment, whereas endoscopic and histologic controls were performed after eight weeks. All the subjects showed a significant reduction of the symptom score (P = 0.001 in the cisapride group; P = 0.002 in the placebo group) without any differences between the two treatment groups. On the other hand, cisapride appeared to significantly improve (P <0.001) the endoscopic lesions of the antral mucosa, which was not observed in the placebo group. Finally, there were no variations in the histological score in either group, probably due to the short period of treatment.

Original languageEnglish
Pages (from-to)156-165
Number of pages10
JournalCurrent Therapeutic Research
Volume47
Issue number1
Publication statusPublished - 1990

Fingerprint

Cisapride
Gastritis
Placebos
Bile Reflux
Duodenogastric Reflux
Endoscopy
Histology
Mucous Membrane
Therapeutics
Antral

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Testoni, P. A., Masci, E., Bagnolo, F., Passaretti, S., Pellegrini, A., Ronchi, G., ... Tittobello, A. (1990). Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial. Current Therapeutic Research, 47(1), 156-165.

Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial. / Testoni, P. A.; Masci, E.; Bagnolo, F.; Passaretti, S.; Pellegrini, A.; Ronchi, G.; Nappi, G.; Tittobello, A.

In: Current Therapeutic Research, Vol. 47, No. 1, 1990, p. 156-165.

Research output: Contribution to journalArticle

Testoni, PA, Masci, E, Bagnolo, F, Passaretti, S, Pellegrini, A, Ronchi, G, Nappi, G & Tittobello, A 1990, 'Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial', Current Therapeutic Research, vol. 47, no. 1, pp. 156-165.
Testoni, P. A. ; Masci, E. ; Bagnolo, F. ; Passaretti, S. ; Pellegrini, A. ; Ronchi, G. ; Nappi, G. ; Tittobello, A. / Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial. In: Current Therapeutic Research. 1990 ; Vol. 47, No. 1. pp. 156-165.
@article{61c319b25cb24aa1925855f2bc3a59a9,
title = "Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial",
abstract = "Thirty-six subjects with endoscopic/histologic diagnosis of chronic reflux antral gastritis and with proven duodenogastric bile reflux were studied in a double-blind trial (cisapride, orally, 10 mg x 4/day vs placebo). The following determinants were considered in the study: endoscopy, histology, and dyspeptic symptoms. All except the endoscopic parameters were evaluated by means of a severity score (0 = absent to 3 = severe). Symptoms were assessed after four and eight weeks of treatment, whereas endoscopic and histologic controls were performed after eight weeks. All the subjects showed a significant reduction of the symptom score (P = 0.001 in the cisapride group; P = 0.002 in the placebo group) without any differences between the two treatment groups. On the other hand, cisapride appeared to significantly improve (P <0.001) the endoscopic lesions of the antral mucosa, which was not observed in the placebo group. Finally, there were no variations in the histological score in either group, probably due to the short period of treatment.",
author = "Testoni, {P. A.} and E. Masci and F. Bagnolo and S. Passaretti and A. Pellegrini and G. Ronchi and G. Nappi and A. Tittobello",
year = "1990",
language = "English",
volume = "47",
pages = "156--165",
journal = "Current Therapeutic Research - Clinical and Experimental",
issn = "0011-393X",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Effect of long-term oral therapy with cisapride in reflux antral gastritis. Results of a double-blind placebo-controlled trial

AU - Testoni, P. A.

AU - Masci, E.

AU - Bagnolo, F.

AU - Passaretti, S.

AU - Pellegrini, A.

AU - Ronchi, G.

AU - Nappi, G.

AU - Tittobello, A.

PY - 1990

Y1 - 1990

N2 - Thirty-six subjects with endoscopic/histologic diagnosis of chronic reflux antral gastritis and with proven duodenogastric bile reflux were studied in a double-blind trial (cisapride, orally, 10 mg x 4/day vs placebo). The following determinants were considered in the study: endoscopy, histology, and dyspeptic symptoms. All except the endoscopic parameters were evaluated by means of a severity score (0 = absent to 3 = severe). Symptoms were assessed after four and eight weeks of treatment, whereas endoscopic and histologic controls were performed after eight weeks. All the subjects showed a significant reduction of the symptom score (P = 0.001 in the cisapride group; P = 0.002 in the placebo group) without any differences between the two treatment groups. On the other hand, cisapride appeared to significantly improve (P <0.001) the endoscopic lesions of the antral mucosa, which was not observed in the placebo group. Finally, there were no variations in the histological score in either group, probably due to the short period of treatment.

AB - Thirty-six subjects with endoscopic/histologic diagnosis of chronic reflux antral gastritis and with proven duodenogastric bile reflux were studied in a double-blind trial (cisapride, orally, 10 mg x 4/day vs placebo). The following determinants were considered in the study: endoscopy, histology, and dyspeptic symptoms. All except the endoscopic parameters were evaluated by means of a severity score (0 = absent to 3 = severe). Symptoms were assessed after four and eight weeks of treatment, whereas endoscopic and histologic controls were performed after eight weeks. All the subjects showed a significant reduction of the symptom score (P = 0.001 in the cisapride group; P = 0.002 in the placebo group) without any differences between the two treatment groups. On the other hand, cisapride appeared to significantly improve (P <0.001) the endoscopic lesions of the antral mucosa, which was not observed in the placebo group. Finally, there were no variations in the histological score in either group, probably due to the short period of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0025177240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025177240&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025177240

VL - 47

SP - 156

EP - 165

JO - Current Therapeutic Research - Clinical and Experimental

JF - Current Therapeutic Research - Clinical and Experimental

SN - 0011-393X

IS - 1

ER -